Glenmark Pharma Launches Polyethylene Glycol 3350 in the US

Glenmark Therapeutics Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., has introduced Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC) in the United States. The product is a generic equivalent of MiraLAX® Powder for Solution by Bayer HealthCare LLC, which is widely used as an osmotic laxative for occasional constipation.

Market Size and Demand

According to reports for a 52-week period ending February 22, 2025, the MiraLAX® Powder for Solution market recorded annual sales of approximately $555.7 million. Glenmark’s entry into this segment comes as an additional supply source in the over-the-counter laxative category.

Polyethylene Glycol 3350 works as an osmotic laxative, drawing water into the colon and aid bowel movements. It is available as an over-the-counter (OTC) product, allowing consumers to access it without a prescription.

Company Statement

Marc Kikuchi, President & Business Head, North America at Glenmark, stated: “We are excited to announce the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful, addressing the growing demand for a new supplier in this category.”

Financials & Market Performance

Glenmark Pharmaceuticals operates in over 80 countries with 11 manufacturing facilities across four continents. The company reported a net profit of ₹348 crore in Q3 FY25, compared to a net loss of ₹449.6 crore in Q3 FY24. Revenue from operations grew 35.1% year-on-year (YoY) to ₹3,387.6 crore for the quarter ending December 31, 2024.

As of March 10, 2025, at 10:50 AM, Glenmark Pharmaceuticals Ltd. was trading at ₹1,398.15, down ₹6.25 (0.45%) for the day. Over the past six months, the stock has declined by 19.08%, but it remains up 46.36% over the past year.

Conclusion 

In conclusion, Glenmark’s Polyethylene Glycol 3350, Powder for Solution will now be available in the U.S. OTC market as a generic alternative to MiraLAX®.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.